Bifidobacterium as an oral delivery carrier of oxyntomodulin for obesity therapy: Inhibitory effects on food intake and body weight in overweight mice

International Journal of Obesity

Volumn 34, Issue 4, 2010, Pages 712-719

  Long, R T ^a   Zeng, W S ^a   Chen, L Y ^a   Guo, J ^b   Lin, Y Z ^b   Huang, Q S ^b   Luo, S Q ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b GUANGDONG PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Bifidobacterium; Body weight; Food intake; Oral administration; Oxyntomodulin (OXM); Transformation

Indexed keywords

AMPICILLIN; ARABINOSE; GHRELIN; GLUCOSE; GREEN FLUORESCENT PROTEIN; OXYNTOMODULIN; SIGNAL PEPTIDE; TETRAHYDROLIPSTATIN; TRIACYLGLYCEROL; XYLAN ENDO 1,3 BETA XYLOSIDASE; ANOREXIGENIC AGENT; DRUG CARRIER; LACTONE; RECOMBINANT PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL STRAIN; BACTERIUM CULTURE; BIFIDOBACTERIUM LONGUM; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG TISSUE LEVEL; ELECTROPORATION; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPRESSION VECTOR; FEMALE; FOOD INTAKE; GENE EXPRESSION PROFILING; GENE EXPRESSION SYSTEM; GENE SEQUENCE; GLUCOSE BLOOD LEVEL; HORMONE BLOOD LEVEL; MOUSE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; NONVIRAL GENE THERAPY; OBESITY; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; RECOMBINANT PLASMID; SEQUENCE ANALYSIS; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT REDUCTION; WESTERN BLOTTING; ANIMAL; BAGG ALBINO MOUSE; BIFIDOBACTERIUM; BLOOD; BODY WEIGHT; DRUG EFFECTS; EATING; GENETICS; METABOLISM; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; PHYSIOLOGY;

ADMINISTRATION, ORAL; ANIMALS; APPETITE DEPRESSANTS; BIFIDOBACTERIUM; BODY WEIGHT; DRUG CARRIERS; EATING; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GHRELIN; LACTONES; MICE; MICE, INBRED BALB C; OBESITY; OXYNTOMODULIN; RECOMBINANT PROTEINS; TRIGLYCERIDES;

BIFIDOBACTERIUM; BIFIDOBACTERIUM LONGUM; MUS; RODENTIA;

EID: 77950864581     PISSN: 03070565     EISSN: 14765497     Source Type: Journal    
DOI: 10.1038/ijo.2009.277     Document Type: Article

References (40)

1. Bataille D, Tatemoto K, Gespach C, Jornvall H, Rosselin G, Mutt V. Isolation of glucagon-37 (bioactive enteroglucagon/oxyntomodulin) from porcine jejuno-ileum. Characterization of the peptide. FEBS Lett 1982; 146: 79-86. (Pubitemid 13254172)
2. Mojsov S, Heinrich G,Wilson IB, Ravazzola M, Orci L, Habener JF. Preproglucagon gene expression in pancreas and intestine diversifies at the level of post-translational processing. J Biol Chem 1986; 261: 11880-11889.
3. Lui EY, Asa SL, Drucker DJ, Lee YC, Brubaker PL. Glucagon and related peptides in fetal rat hypothalamus in vivo and in vitro. Endocrinology 1990; 126: 110-117.
4. Dubrasquet M, Bataille D, Gespach C. Oxyntomodulin (glucagon- or bioactive enteroglucagon): a potent inhibitor of pentagastrin- stimulated acid secretion in rats. Biosci Rep 1982; 2: 391-395.
5. Schjoldager B, Mortensen PE, Myhre J, Christiansen J, Holst JJ. Oxyntomodulin from distal gut. Role in regulation of gastric and pancreatic functions. Dig Dis Sci 1989; 34: 1411-1419.
6. Ghatei MA, Uttenthal LO, Christofides ND, Bryant MG, Bloom SR. Molecular forms of human enteroglucagon in tissue and plasma: plasma responses to nutrient stimuli in health and in disorders of the upper gastrointestinal tract. J Clin Endocrinol Metab 1983; 57: 488-495.
7. Besterman HS, Cook GC, Sarson DL, Christofides ND, Bryant MG, Gregor M et al. Gut hormones in tropical malabsorption. Br Med J 1979; 2: 1252-1255.
8. Sarson DL, Scopinaro N, Bloom SR. Gut hormone changes after jejunoileal (JIB) or biliopancreatic (BPB) bypass surgery for morbid obesity. Int J Obes 1981; 5: 471-480.
9. Holst JJ, Sorensen TI, Andersen AN, Stadil F, Andersen B, Lauritsen KB et al. Plasma enteroglucagon after jejunoileal bypass with 3:1 or 1:3 jejunoileal ratio. Scand J Gastroenterol 1979; 14: 205-207.
10. Dakin CL, Gunn I, Small CJ, Edwards CM, Hay DL, Smith DM et al. Oxyntomodulin inhibits food intake in the rat. Endocrinology 2001; 142: 4244-4250.
11. Dakin CL, Small CJ, Batterham RL, Neary NM, Cohen MA, Patterson M et al. Peripheral oxyntomodulin reduces food intake and body weight gain in rats. Endocrinology 2004; 145: 2687-2695.
12. Wynne K, Park AJ, Small CJ, Patterson M, Ellis SM, Murphy KG et al. Subcutaneous oxyntomodulin reduces body weight in overweight and obese subjects: a double-blind, randomized, controlled trial. Diabetes 2005; 54: 2390-2395.
13. Baggio LL, Huang Q, Brown TJ, Drucker DJ. Oxyntomodulin and glucagon-like peptide-1 differentially regulate murine food intake and energy expenditure. Gastroenterology 2004; 127: 546-558.
14. Wynne K, Bloom S. Oxyntomodulin: a new therapy for obesity? Sci Sch Autumn 2007; 6: 25-29.
15. De Simone C, Rosati E, Moretti S, Salvadori B, Vesely R, Jirillo E. Probiotics and stimulation of the immune response. Eur J Clin Nutr 1991; 45: 32-34.
16. Elmer GW, Surawicz CM, McFarl LV. Biotherapeutic agents. A neglected modality for the treatment and prevention of selected intestinal and vaginal infections. JAMA 1996; 275: 870-8766.
17. Orrhage K, Sillerstrom E, Gustafsson JA, Nord CE, Rafter J. Binding of mutagenic heterocyclic amines by intestinal and lactic acid bacteria. Mutat Res 1994; 311: 239-248.
18. Singh J, Rivenson A, TomitaM, Shimamura S, Ishibashi N, Reddy BS. Bifidobacterium longum, a lactic acid-producing intestinal bacterium inhibits colon cancer and modulates the intermediate biomarkers of colon carcinogenesis. Carcinogenesis 1997; 18: 833-841.
19. Nakamura T, Sasaki T, Fujimori M. Cloned cytosine deaminase gene expression of Bifidobacterium longum and application to enzyme/pro-drug therapy of hypoxic solid tumors. Biosci Biotechnol Biochem 2002; 66: 2362-2366.
20. Li X, Fu GF, Fan YR, Liu WH, Liu XJ, Wang JJ et al. Bifidobacterium adolescentis as a delivery system of endostatin for cancer gene therapy: selective inhibitor of angiogenesis and hypoxic tumor growth. Cancer Gene Ther 2003; 10: 105-111.
21. Escogido MLR, Rodríguez ADL, de la Rosa APB. A novel binary expression vector for production of human IL-10 in Escherichia coli and Bifidobacterium longum. Biotechnol Lett 2007; 29: 1249-1253.
22. Moon GS, Pyun YR, Park MS, Ji GE, Kim WJ. Secretion of recombinant pediocin PA-1 by Bifidobacterium longum, Using the signal sequence for bifidobacterial a-amylase. Appl Environ Microbiol 2005; 72: 5630-5632.
23. Zhu ZS, Wang LS, Zeng WS, Zheng YJ, Luo SQ, Li YX et al. Isolation and identification of a Bifidobacterium strain with a plasmid polymerase by PCR. J Microecol (China) 2007; 19: 321-323.
24. Argnani A, Leer RJ, van Luijk N, Pouwels PH. A convenient and reproducible method to genetically transform bacteria of the genus Bifidobacterium. Microbiology 1996; 142: 109-114.
25. De Roos NM, Katan MB. Effects of probiotic bacteria on diarrhea, lipid metabolism, and carcinogenesis: a review of papers published between 1988 and 1998. Am J Clin Nutr 2000; 71: 405-411.
26. Xiao JZ, Kondo S, Takahashi N, Miyaji K, Oshida K, Hiramatsu A et al. Effects of milk products fermented by Bifidobacterium longum on blood lipids in rats and healthy adult male volunteers. J Dairy Sci 2003; 86: 2452-2461.
27. Ataie-Jafari A, Larijani B, Majd HA, Tahbaz F. Cholesterollowering effect of probiotic yogurt in comparison with ordinary yogurt in mildly to moderately hypercholesterolemic subjects. Ann Nutr Metab 2009; 54: 22-27.
28. Castell JV, Friedrich G, Kuhn CS, Poppe GE. Intestinal absorption of undegraded proteins in men: presence of bromelain in plasma after oral intake. Gastrointest Liver Physiol 1997; 273: 139-146.
29. Worthington BS, Boatman ES, Kenny GE. Intestinal absorption of intact proteins in normal and protein-deficient rats. Am J Clin Nutr 1974; 27: 276-286.
30. Gros L, Thorens B, Bataille D, Kervran A. Glucagon-like peptide-1- (7-36) amide, oxyntomodulin, and glucagon interact with a common receptor in a somatostatin-secreting cell line. Endocrinology 1993; 133: 631-638.
31. ScheppW, Dehne K, Riedel T, Schmidtler J, Schaffer K, Classen M. Oxyntomodulin: a cAMP-dependent stimulus of rat parietal cell function via the receptor for glucagon-like peptide-1 (7-36) NH2. Digestion 1996; 57: 398-405.
32. Wei Y, Mojsov S. Tissue-specific expression of the human receptor for glucagon-like peptide-I: brain, heart and pancreatic forms have the same deduced amino acid sequences. FEBS Lett 1995; 358: 219-224.
33. Bullock B, Heller R, Habener J. Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor. Endocrinology 1996; 137: 2968-2978.
34. Lin CW, Miller TR. Both CCK-A and CCK-B/gastrin receptors are present on rabbit vagus nerve. Am J Physiol Regul Integr Comp Physiol 1992; 263: 591-595.
35. Corp ES, Smith GP. Characterization of axonally transported [125I]PYY binding sites in rat vagus nerve. Brain Res 1991; 553: 175-179.
36. Anini Y, Jarrousse C, Chariot J, Nagain C, Yanaihara N, Sasaki K et al. xyntomodulin inhibits pancreatic secretion through the nervous system in rats. Pancreas 2000; 20: 348-360.
37. Cummings DE, Purnell JQ, Frayo RS, Schmidova K, Wisse BE, Weigle DS. A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans. Diabetes 2001; 50: 1714-1719.
38. Cummings DE, Frayo RS, Marmonier C, Aubert R, Chapelot D. Plasma ghrelin levels and hunger scores in humans initiating meals voluntarily without time- and food-related cues. Am J Physiol Endocrinol Metab 2004; 287: E297-E304.
39. Dakin CL, Small CJ, Park AJ, Seth A, Ghatei MA, Bloom SR. Repeated ICV administration of oxyntomodulin causes a greater reduction in body weight gain than in pair-fed rats. Am J Physiol Endocrinol Metab 2002; 283: E1173-E1177.
40. Patterson M, Murphy KG, Patel SR, Patel NA, Greenwood HC, Cooke JH et al. Hypothalamic injection of oxyntomodulin suppresses circulating ghrelin-like immunoreactivity. Endocrinology 2009; 150: 3513-3520.